文献速递妇科

子宫内膜癌宫腔镜下注射示踪剂行前哨淋巴结定位:单中心200余例评估

Sentinel node mapping in endometrial cancer following Hysteroscopic injection of tracers: A single center evaluation over 200 cases.
PubMed 文献 · Gynecol Oncol · 2017-07-05

该单中心评估分析了2005年1月至2017年2月202例子宫内膜癌患者宫腔镜下瘤周注射示踪剂后行前哨淋巴结定位的检出率与诊断准确性,并比较ICG与Tc99m两种示踪剂。总体检出率93.2%(179/192),双侧盆腔检出率59.7%(107/179),ICG组双侧检出率高于Tc99m组(72.8% vs 53.3%,p=0.012)。总体灵敏度86.4%(95%CI 68.4-100),阴性预测值96.4%(95%CI 86.7-100),两种示踪剂间无差异。

要点

  • 宫腔镜下注射示踪剂行前哨淋巴结定位总体检出率93.2%(179/192)。
  • ICG组双侧盆腔检出率72.8%,高于Tc99m组的53.3%(p=0.012)。
  • 3例假阴性均发生在Tc99m组,均为孤立主动脉转移且盆腔淋巴结阴性。

核心结论

  • 子宫内膜癌宫腔镜下注射示踪剂行前哨淋巴结定位的准确性与宫颈注射相当,且主动脉区检出率更高。
  • ICG可提高双侧检出率。
  • 原文结论指出该主题需进一步研究。

研究设计与样本

  • 单中心评估,纳入2005年1月至2017年2月接受宫腔镜下瘤周注射示踪剂后行前哨淋巴结定位±淋巴结清扫的子宫内膜癌患者,共202例操作。
  • 平均年龄60岁(范围28-82),平均BMI 26.8 kg/m2(范围15-47)。
  • 133例(65.8%)的子宫切除与定位操作经腹腔镜完成。
  • 比较ICG与Tc99m两种示踪剂的检出率与诊断准确性。

主要发现

  • 总体检出率93.2%(179/192),10例被排除(9例技术设备故障,1例迷走神经反应)。
  • 双侧盆腔定位占59.7%(107/179),ICG组为72.8%,Tc99m组为53.3%(p=0.012)。
  • 50.8%(91/179)的病例前哨淋巴结同时位于盆腔与主动脉区,5例(2.8%)仅位于主动脉区。
  • 平均检出前哨淋巴结数3.7枚(范围1-8)。
  • 22例(12.3%)有淋巴结受累:大转移10例(45.5%)、微转移5例(22.7%)、孤立肿瘤细胞7例(31.8%);仅主动脉淋巴结阳性6例(27.3%),盆腔与主动脉均阳性5例(22.7%),仅盆腔阳性11例(50%)。

局限性

  • 原文结论指出该主题需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyze detection-rate(DR) and diagnostic-accuracy (A) of sentinel-nodes(SLNs) mapping following hysteroscopic-injection of tracer. To compare DR and A between tracers: ICG and Tc99m. METHODS: Evaluation of endometrial-cancer patients who underwent SLNs mapping after hysteroscopic-peritumoral-injection of tracer±lymphadenectomy. Analysis of DR (overall-bilateral-aortic) and A in the entire cohort and comparison between tracers. RESULTS: 202 procedures were performed from January/2005 to February/2017. Mean age:60years (28-82); mean BMI: 26.8 kg/m2 (15-47). In 133 cases (65.8%) hysterectomy and mapping procedure were performed laparoscopically. The overall-DR of the technique was 93.2% (179/192) (10 cases were excluded: 9 for technical-equipment failure; 1 for vagal reaction). Bilateral pelvic mapping was found in 59.7% of cases (107/179) and was more frequent in the ICG group (72.8% vs 53.3%; p: 0.012). In 50.8% of cases (91/179) SLNs were mapped both in pelvic and aortic nodes, and in 5 cases (2.8%) only in the aortic area. The mean number of detected SLNs was 3.7 (1-8). 22 patients (12.3%) had nodal involvement: 10-(45.5%)-macrometastases; 5-(22.7%)-micrometastases; 7-(31.8%)-ITCs. In 6 cases (27.3%) only aortic nodes were positive; in 5 cases (22.7%) both pelvic and aortic nodes and in 11 cases (50%) only pelvic nodes were involved. Three false-negative results were found, all in the Tc99m group. All had isolated aortic metastases with negative pelvic nodes. Overall-sensitivity was 86.4% (95%CI: 68.4-100) and overall-negative-predictive-value (NPV) was 96.4% (95%CI 86.7-100). No differences in terms of overall-DR, overall-sensitivity and overall-NPV were found between the two tracers. CONCLUSIONS: Hysteroscopic-injection of tracer for SLNs mapping in endometrial cancer is as accurate as cervical injection with a higher DR in the aortic area. ICG improves bilateral-DR. Further investigation is warranted on this topic.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Martinelli F, Ditto A, Signorelli M, et al. Sentinel node mapping in endometrial cancer following Hysteroscopic injection of tracers: A single center evaluation over 200 cases. Gynecol Oncol. 2017. PMID: 28625394. doi:10.1016/j.ygyno.2017.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。